Evidence map›Paper›PMID 40139888›Full record

Trial reportJournal of the American College of Cardiology2025

Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial.

David J Maron, Jonathan D Newman, Rebecca Anthopolos, Ying Lu, Susanna Stevens, William E Boden, Kreton Mavromatis, Jason Linefsky, Rajesh G Nair, Olga Bockeria and 18 more

Registry-linked trialAbstract readObservational StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American College of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01471522 (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01471522 nacompletednot on this map

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

TypeinterventionalSponsorNYU Langone HealthRan2012 to 2023Enrolled5,179ConditionsCardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart DiseasesArmscardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Sex differences in coronary disease health Status outcomes: the ISCHEMIA trial.European heart journal. Quality of care & clinical outcomes · 2026
    Trial
  2. Article
  3. Article
  4. Tracing the evolution of cardiology: Pioneering discoveries and paradigm shifts in cardiovascular care.American heart journal plus : cardiology research and practice · 2026
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

David J MaronDepartment of Medicine, Stanford Prevention Research Center and Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA. Electronic address: david.maron@stanford.edu.
Jonathan D NewmanDepartment of Medicine, Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, New York, New York, USA.
Rebecca AnthopolosNYU Grossman School of Medicine, New York, New York, USA.
Ying LuNYU Grossman School of Medicine, New York, New York, USA.
Susanna StevensDuke Clinical Research Institute, Durham, North Carolina, USA.
William E BodenVA New England Healthcare System, Bedford, Massachusetts, USA.
Kreton MavromatisAtlanta VA Healthcare System, Atlanta, Georgia, USA; Emory University School of Medicine, Atlanta, Georgia, USA.
Jason LinefskyAtlanta VA Healthcare System, Atlanta, Georgia, USA; Emory University School of Medicine, Atlanta, Georgia, USA.
Rajesh G NairGovernment Medical College, Kerala, India.
Olga BockeriaNational Research Center for Cardiovascular Surgery, Moscow, Russia.
Gilbert GosselinMontreal Heart Institute, Montreal, Quebec, Canada.
Gian P PernaCardiology and ICCU - Ospedali Riuniti Ancona, Marche, Italy.
Elena DemchenkoAlmazov National Medical Research Centre, Saint Petersburg, Russia.
David FooYong Loo Lin School of Medicine, Singapore, Singapore.
Michael D ShapiroWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Mary Ann ChampagneStanford University School of Medicine, Stanford, California, USA.
Christie BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Peter McCulloughMcCullough Foundation, Dallas, Texas, USA.
Jose Luis Lopez-SendonHospital Universitario La Paz, Madrid, Spain.
Frank RockholdDuke Clinical Research Institute, Durham, North Carolina, USA.
Frank HarrellDepartment of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
Yves RosenbergNational Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
Gregg W StoneThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sripal BangaloreDepartment of Medicine, Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, New York, New York, USA.
Harmony R ReynoldsDepartment of Medicine, Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, New York, New York, USA.
John A SpertusSaint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City's Healthcare Institute for Innovations in Quality, Kansas City, Missouri, USA.
Judith S HochmanDepartment of Medicine, Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, New York, New York, USA.
ISCHEMIA Research Group

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
NCATS NIH HHS UL1 TR001445NHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

backgroundGuideline-directed medical therapy (GDMT) with multiple risk factor goals is recommended for patients with chronic coronary disease (CCD), yet achieving all GDMT goals is uncommon. The relative importance of these goals and timing of their attainment on cardiovascular events is uncertain.

objectivesThis study aims to describe the relationship between achieving specific GDMT goals, when they are achieved, and clinical outcomes.

methodsThis was an observational study of participants with CCD in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial. The primary outcome was cardiovascular (CV) death or myocardial infarction (MI). GDMT goals were systolic blood pressure (SBP) <130 mm Hg, low-density lipoprotein cholesterol <70 mg/dL, not smoking, and antiplatelet therapy. Frequency of GDMT goals met at baseline and during follow-up is described. Bayesian joint modeling for longitudinal goal status and time-to-event analyses characterized the relative importance of specific GDMT goal attainment and timing with CV death/MI.

resultsAll 5,179 ISCHEMIA participants were included. Among 4,914 participants with complete data on all 4 GDMT goals at baseline, 386 (9%), 2,073 (42%), 1,843 (38%), and 612 (12%) met 0-1, 2, 3, and 4 GDMT goals, respectively. The 4-year cumulative event rate for CV death/MI was highest for participants who attained no GDMT goals (24.5%; 95% credible interval [CrI]: 13.5%-42.2%) and lowest for those who attained all goals at baseline and remained at goal during follow-up (8.7%; 95% CrI: 6.7%-10.9%). SBP goal attainment was associated with a significant absolute event reduction in CV death/MI (-5.1%; 95% CrI: -11.3% to -1.0%), followed by antiplatelet therapy (-11.2%; 95% CrI: -29.1% to 0.8%), achieving low-density lipoprotein cholesterol <70 mg/dL (-2.0%; 95% CrI: -6.0% to 2.4%), and not smoking (-1.7%; 95% CrI: -9.3% to 4.2%). Ten millimeters of mercury lower SBP during follow-up was associated with 10% relative risk reduction of CV death/MI (RR [relative risk] = 0.90; 95% CrI: 0.82-0.98), after adjusting for other GDMT goals and baseline characteristics.

conclusionsAmong participants with CCD, early attainment and maintenance of GDMT goals, especially SBP, were associated with fewer cardiovascular events. Compared with no GDMT goals at target, having all 4 GDMT goals at target at baseline was associated with an absolute 16% fewer CV deaths and MIs. (ISCHEMIA [International Study of Comparative Health Effectiveness With Medical and Invasive Approaches]; NCT01471522).

Indexed as

Myocardial IschemiaPractice Guidelines as TopicAgedFemaleHumansMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsTreatment OutcomePlatelet Aggregation Inhibitorschronic coronary diseaseguideline-directed medical therapylifestyleoptimal medical therapysecondary prevention

Identifiers

PMID40139888
PMCPMC12122066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.